4502 Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,102.00 |
| 52 Week High | JP¥4,873.00 |
| 52 Week Low | JP¥3,900.00 |
| Beta | 0.54 |
| 1 Month Change | -0.63% |
| 3 Month Change | -7.49% |
| 1 Year Change | -9.85% |
| 3 Year Change | 9.15% |
| 5 Year Change | 6.55% |
| Change since IPO | 203.85% |
Recent News & Updates
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings
May 21
Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next
May 12Recent updates
Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings
May 21Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next
May 12Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00
Mar 28Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00
Mar 13Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00
Feb 26Shareholder Returns
| 4502 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -1.4% | -0.1% | 0.8% |
| 1Y | -9.8% | 2.3% | 24.8% |
Return vs Industry: 4502 underperformed the JP Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: 4502 underperformed the JP Market which returned 24.8% over the past year.
Price Volatility
| 4502 volatility | |
|---|---|
| 4502 Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4502 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4502's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,095 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| 4502 fundamental statistics | |
|---|---|
| Market cap | JP¥6.44t |
| Earnings (TTM) | JP¥144.07b |
| Revenue (TTM) | JP¥4.26t |
44.7x
P/E Ratio1.5x
P/S RatioIs 4502 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4502 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.26t |
| Cost of Revenue | JP¥1.43t |
| Gross Profit | JP¥2.84t |
| Other Expenses | JP¥2.69t |
| Earnings | JP¥144.07b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 91.82 |
| Gross Margin | 66.54% |
| Net Profit Margin | 3.38% |
| Debt/Equity Ratio | 66.6% |
How did 4502 perform over the long term?
See historical performance and comparison